Evidence map›Paper›PMID 32472393›Full record

ArticleJournal of molecular neuroscience : MN2020

Knockdown of Amphiregulin Triggers Doxorubicin-Induced Autophagic and Apoptotic Death by Regulating Endoplasmic Reticulum Stress in Glioblastoma Cells.

I-Neng Lee, Jen-Tsung Yang, Ming-Ju Hsieh, Cheng Huang, Hsiu-Chen Huang, Yu-Ju Ku, Yu-Ping Wu, Kuan-Chieh Huang, Jui-Chieh Chen

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular neuroscience : MN, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

I-Neng LeeDepartment of Medical Research, Chang Gung Memorial Hospital, Chiayi, 61363, Taiwan.
Jen-Tsung YangDepartment of Neurosurgery, Chang Gung Memorial Hospital, Chiayi, 61363, Taiwan.
Ming-Ju HsiehOral Cancer Research Center, Changhua Christian Hospital, Changhua, 500, Taiwan.
Cheng HuangDepartment of Biotechnology and Laboratory Science in Medicine, National Yang-Ming University, Taipei, 112, Taiwan.
Hsiu-Chen HuangDepartment of Applied Science, National Tsing Hua University, South Campus, No. 521, Nanda Road, Hsinchu, 30014, Taiwan.
Yu-Ju KuThe Center for General Education of China Medical University, China Medical University, Taichung, 404, Taiwan.
Yu-Ping WuCollege of Medicine, Chang Gung University, Tao-Yuan, 33302, Taiwan.
Kuan-Chieh HuangDepartment of Biochemical Science and Technology, National Chiayi University, Chiayi, 60004, Taiwan.
Jui-Chieh ChenDepartment of Biochemical Science and Technology, National Chiayi University, Chiayi, 60004, Taiwan. jcc@mail.ncyu.edu.tw.ORCID http://orcid.org/0000-0002-4976-8980
Chang Gung University · TWNational Chiayi University · TWChiayi Chang Gung Memorial Hospital · TWChina Medical University · TWMingDao University · TWNational Tsing Hua University · TWNational Yang Ming Chiao Tung University · TW

Funding

Chiayi Chang Gung Memorial Hospital CMRPG6F0351, CMRPG6F0352, and CMRPG6F0353Ministry of Science and Technology, Taiwan 107-2314-B-415-002-
6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) is the most common type of malignant brain tumor. The present standard treatment for GBM has not been effective; therefore, the prognosis remains dramatically poor and prolonged survival after treatment is still limited. The new therapeutic strategies are urgently needed to improve the treatment efficiency. Doxorubicin (Dox) has been widely used in the treatment of many cancers for decades. In recent years, with the advancement of delivery technology, more and more research indicates that Dox has the opportunity to be used in the treatment of GBM. Amphiregulin (AREG), a ligand of the epidermal growth factor receptor (EGFR), has been reported to have oncogenic effects in many cancer cell types and is implicated in drug resistance. However, the biological function and molecular mechanism of AREG in Dox treatment of GBM are still unclear. Here, we demonstrate that knockdown of AREG can boost Dox-induced endoplasmic reticulum (ER) stress to trigger activation in both autophagy and apoptosis in GBM cells, ultimately leading to cell death. To explore the importance of AREG in the clinic, we used available bioinformatics tools and found AREG is highly expressed in GBM tumor tissues that are associated with poor survival. In addition, we also used antibody array analysis to dissect pathways that are likely to be activated by AREG. Taken together, our results revealed AREG can serve as a potential therapeutic target and a promising biomarker in GBM.

Indexed as

ApoptosisAutophagyEndoplasmic Reticulum StressAmphiregulinAntineoplastic AgentsBiomarkers, TumorBrain NeoplasmsCell Line, TumorDoxorubicinGlioblastomaHumansNeuronsAmphiregulinAntineoplastic AgentsAREG protein, humanBiomarkers, TumorDoxorubicinAmphiregulinAutophagyDoxorubicinDrug resistanceEndoplasmic reticulum (ER) stressGlioblastoma multiforme (GBM)

Identifiers

PMID32472393
OpenAlexW3029684013

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.